Navigation Links
Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jun 4, 2007 - Acorda Therapeutics, Inc.(R) (Nasdaq: ACOR) today announced that the Company presented a "meta-analysis" or combined analysis of two clinical trials of Fampridine-SR in multiple sclerosis during a poster session at the Americas Committee for Treatment and Research in MS (ACTRIMS) Meeting in Washington, D.C. on Saturday, June 2, 2007. The poster, "Validation of Consistent Improvement in Walking Speed on the Timed 25 Foot Walk as a Measure of Clinically Meaningful Change," was presented by Andrew Goodman, M.D., Director of the Multiple Sclerosis Center at the University of Rochester.

The objective of the analysis was to validate a consistent response criterion as a measure of clinically meaningful change. A consistent timed walk responder was defined as a subject whose walking speeds for at least three of the four on-treatment visits were faster than the fastest speed across any of their five non-treatment visits. In both studies, Fampridine-SR treatment was associated with significantly increased probability of this response compared to placebo (p less than 0.001). Both clinical trials were double-blind, placebo-controlled, parallel group, multi-center studies. The analysis was designed after the data from the first study were available. A total of 501 patients were included in the analysis.

The clinical meaningfulness of this response criterion was assessed primarily by use of the 12-Item MS Walking Scale (MSWS-12), a questionnaire in which the patient rates the clinical impact of his or her walking disability on activities of daily life. Additional criteria for clinical meaningfulness included a seven-point Subject Global Impression (SGI) and a seven-point Clinician Global Impression (CGI). In the meta-analysis, timed-walk responders had significantly greater average improvements from baseline in the MSWS-12 score than the non-responders in both studies in
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Acorda Therapeutics Presents Fampridine Data ACTRIMS Meeting
(Date:7/25/2014)... Kan. , July 25, 2014 /PRNewswire-iReach/ -- ... and TCGRx, of Powers Lake, Wisconsin ... partners in a distribution and co-marketing agreement allowing ... retail pharmacies throughout the United States ... robotics-based pharmacy management and workflow systems to retail ...
(Date:7/25/2014)... , July 25, 2014  CVS Caremark Corporation (NYSE: ... call on Tuesday, August 5, 2014, at 8:30 a.m. ... quarter 2014 financial results. An audio webcast ... the Investor Relations portion of the CVS Caremark website ... http://info.cvscaremark.com/investors . This webcast will be archived and ...
(Date:7/25/2014)... Trinidad and Tobago , July 25, 2014 ... the Trinidad & Tobago Ministry of Health approved ... therapy that significantly increases the cure rate from ... infected with the genotype 1 virus. Telaprevir is ... the trade brand INCIVO®. Photo - ...
Breaking Medicine Technology:ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
... The University of Oxford Clinical Trial,Service Unit ... results of the SEAS trial of ezetimibe should ... the SHARP and,IMPROVE-IT trials of ezetimibe, and reporting ... independently of the drug,manufacturers., The two hypothesis-testing ...
... clinicians identify risk in patients, including ... BIRMINGHAM, Ala., July 21 Using the ... link between,adiponectin and heart disease progression. The information ... cholesterol and heart,disease risk-lowering treatments in at-risk patients., ...
Cached Medicine Technology:Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 2Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 3VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis 2VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis 3
(Date:7/25/2014)... neurons and reduce motor deficits in a rat ... School of Medicine have shown. , The results ... Disease . , The findings demonstrate that the ... sufficient levels and have beneficial effects when administered ... studies of XPro1595 in animals tested more invasive ...
(Date:7/25/2014)... announced the launch of its ASA Perioperative Surgical ... to improve the patient experience before, during and ... care organizations from across the country will participate ... first time at the ASA,s PSH Learning Collaborative ... PSH collaborative participants will create a network where ...
(Date:7/25/2014)... Florida (PRWEB) July 25, 2014 ... its co-founders, professional stuntman and parkour instructor, Jared “JJ” ... extreme sports competition show, American Ninja Warrior. The show ... 28th at 9PM and will rerun on the new ... Woods, a long-time Miami resident, has been balancing careers ...
(Date:7/25/2014)... NJ (PRWEB) July 25, 2014 CarePoint ... Dr. Edward Boylan, has joined our network, CarePoint ... the community. Hundreds of highly skilled and experienced physicians ... top doctors and practices in Hudson County, representing a ... Health’s commitment to provide the highest quality care to ...
(Date:7/25/2014)... Eye & Vision has announced the celebration ... by expanding a new specialized ocular and vision service ... clinic. , By acquiring specialized Visual Evoked Potential (VEP) ... problems, patients with vision loss in need of visual ... implementation of this specialized vision testing clinic. The new ...
Breaking Medicine News(10 mins):Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 3Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:Dr. Boylan Joins CarePoint Health Medical Group 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3
... belief that adolescent boys tend to take romance for a ... to heart matters, they might not be so fleeting after ... outside, an adolescent boy fails to communicate his emotions, leading ... ,Boys are more vulnerable and emotionally engaged in romantic ...
... at the University of California, appearing in the latest ... says that people// with autism never "daydream" The researchers ... of people having autism and those not affected by ... the brain, emotions and thoughts are processed. However this ...
... India Institute of Medical Sciences (AIIMS) here is running short ... than sanctioned//, Rajya Sabha was informed Friday. ,Replying to ... Panabaka Lakshmi said that the AIIMS was running with just ... ,She also informed the house that during 2003-05, ...
... Economy Research Institute at the University of Massachusetts listed ... air pollution//. This list is officially called the Toxic ... source of air pollution. This is based on air ... the United States. , The various factors ...
... in Australia's medical schools have become so inadequate that ... parts even confusing// certain vital organs with each other. ... have raised concerns that medical students are not being ... the students are not properly trained in anatomy. According ...
... of Medical Sciences (RIMS) is organising a three-day intensive ... states from today// the 11th April. This course is ... the shortfall of sports medicine specialists in the Northeast; ... ,Professor L Fimate the RIMS director, while addressing ...
Cached Medicine News:Health News:Teenage Boys More Vulnerable And Emotionally Engaged In Romantic Relationships 2Health News:Teenage Boys More Vulnerable And Emotionally Engaged In Romantic Relationships 3
... Mapping. Biosense Webster offers a complete ... SANTORO Fixed Catheter is designed for ... the coronary sinus. The pair of ... tip permit pacing in the coronary ...
Standard Deflectable Catheters...
... Soft HIS diagnostic catheters provide ... designed curve that allows for ... HIS bundle. In addition, the ... reduce the risk of perforation ...
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures....
Medicine Products: